Profile data is unavailable for this security.
About the company
Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of ITK inhibition as a new approach to immunotherapy for a range of cancer and immune diseases. Its lead product candidate is soquelitinib, a selective, covalent inhibitor of ITK (interleukin 2 inducible T cell kinase) and is in a multi-center Phase 1/1b clinical trial in patients with various recurrent, malignant T cell lymphomas. Soquelitinib is designed to inhibit the proliferation of certain malignant T cells. Its second product candidate, ciforadenant, is an oral, small molecule antagonist of the A2A receptor for adenosine designed to disable a tumor’s ability to subvert attack by the immune system by blocking the binding of immunosuppressive adenosine in the tumor microenvironment to the A2A receptor. The Company’s third product candidate is mupadolimab, a humanized monoclonal antibody that is designed to react with a specific site on CD73.
- Revenue in USD (TTM)0.00
- Net income in USD-24.86m
- Incorporated2014
- Employees28.00
- LocationCorvus Pharmaceuticals Inc863 Mitten Rd Ste 102BURLINGAME 94010-1311United StatesUSA
- Phone+1 (650) 900-4520
- Fax+1 (302) 655-5049
- Websitehttps://www.corvuspharma.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
CytomX Therapeutics Inc | 119.18m | 16.53m | 102.85m | 120.00 | 6.67 | -- | 5.54 | 0.863 | 0.1978 | 0.1978 | 1.53 | -0.4649 | 0.5684 | -- | 16.71 | 993,150.00 | 7.89 | -21.53 | 26.77 | -32.32 | -- | -- | 13.87 | -100.38 | -- | -- | -- | -- | 90.38 | 11.21 | 99.43 | -- | -26.01 | -- |
Immunic Inc | 0.00 | -97.92m | 103.59m | 77.00 | -- | 1.24 | -- | -- | -1.84 | -1.84 | 0.00 | 0.9278 | 0.00 | -- | -- | 0.00 | -91.94 | -72.09 | -110.91 | -80.11 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 22.25 | -- | -10.97 | -- |
Annovis Bio Inc | 0.00 | -47.53m | 103.67m | 6.00 | -- | -- | -- | -- | -5.04 | -5.04 | 0.00 | -0.3046 | 0.00 | -- | -- | 0.00 | -284.97 | -106.31 | -411.92 | -124.71 | -- | -- | -- | -- | -- | -9.20 | -- | -- | -- | -- | -121.90 | -- | -- | -- |
Oramed Pharmaceuticals, Inc. | 674.00k | 10.46m | 104.62m | 15.00 | 10.35 | 0.6261 | 10.01 | 155.22 | 0.2488 | 0.2488 | 0.0165 | 4.11 | 0.0037 | -- | -- | 44,933.33 | 5.63 | -- | 6.27 | -- | -- | -- | 1,518.25 | -- | -- | -- | 0.162 | -- | -50.43 | -- | 115.11 | -- | -- | -- |
aTyr Pharma Inc | 588.00k | -53.93m | 104.90m | 56.00 | -- | 1.23 | -- | 178.40 | -0.9029 | -0.9029 | 0.0099 | 1.24 | 0.0047 | -- | 0.2868 | 10,500.00 | -43.13 | -45.45 | -48.85 | -52.74 | -- | -- | -9,172.11 | -784.19 | -- | -- | 0.021 | -- | -96.60 | -- | -11.14 | -- | 47.98 | -- |
Seres Therapeutics Inc | 126.85m | -82.68m | 106.16m | 233.00 | -- | -- | -- | 0.837 | -0.6062 | -0.6062 | 0.9495 | -0.3945 | 0.4149 | -- | -- | 544,407.80 | -27.04 | -41.51 | -36.82 | -54.13 | -- | -- | -65.18 | -170.14 | 1.25 | -9.21 | 2.41 | -- | 1,672.24 | 34.91 | 54.54 | -- | 32.72 | -- |
DiaMedica Therapeutics Inc | 0.00 | -19.26m | 106.30m | 18.00 | -- | 2.29 | -- | -- | -0.5532 | -0.5532 | 0.00 | 1.22 | 0.00 | -- | -- | 0.00 | -48.47 | -45.38 | -52.02 | -48.24 | -- | -- | -- | -- | -- | -- | 0.00006 | -- | -- | -- | -41.72 | -- | -13.65 | -- |
PDS Biotechnology Corp | 0.00 | -43.89m | 108.20m | 25.00 | -- | 2.91 | -- | -- | -1.37 | -1.37 | 0.00 | 1.01 | 0.00 | -- | -- | 0.00 | -63.85 | -51.63 | -74.22 | -59.00 | -- | -- | -- | -- | -- | -27.82 | 0.3933 | -- | -- | -- | -5.11 | -- | -- | -- |
Corvus Pharmaceuticals Inc | 0.00 | -24.86m | 111.34m | 28.00 | -- | 2.62 | -- | -- | -0.5113 | -0.5113 | 0.00 | 0.6804 | 0.00 | -- | -- | 0.00 | -50.58 | -38.31 | -59.70 | -43.34 | -- | -- | -- | -- | -- | -12.88 | 0.00 | -- | -- | -- | 34.57 | -- | -37.45 | -- |
Omega Therapeutics Inc | 4.94m | -92.28m | 114.17m | 93.00 | -- | 2.76 | -- | 23.12 | -1.67 | -1.67 | 0.0896 | 0.7498 | 0.029 | -- | 6.08 | 53,107.53 | -54.28 | -- | -62.10 | -- | -- | -- | -1,868.35 | -- | -- | -- | 0.302 | -- | 49.25 | -- | 5.13 | -- | -- | -- |
Regulus Therapeutics Inc | 0.00 | -31.37m | 115.22m | 28.00 | -- | 1.07 | -- | -- | -1.46 | -1.46 | 0.00 | 1.64 | 0.00 | -- | -- | 0.00 | -41.50 | -53.74 | -45.91 | -76.96 | -- | -- | -- | -715.58 | -- | -- | 0.005 | -- | -- | -- | -6.05 | -- | 94.54 | -- |
Kodiak Sciences Inc | 0.00 | -232.75m | 117.68m | 107.00 | -- | 0.4878 | -- | -- | -4.44 | -4.44 | 0.00 | 4.59 | 0.00 | -- | -- | 0.00 | -43.30 | -31.73 | -47.44 | -33.61 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 21.97 | -- | 134.76 | -- |
Tevogen Bio Holdings Inc | 0.00 | -67.33k | 118.11m | 17.00 | -- | -- | -- | -- | -0.0004 | -0.0004 | 0.00 | -0.0045 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -8.19 | 1.74 | -- | -- | -- | 99.69 | -- | -- | -- |
Nuvectis Pharma Inc | 0.00 | -22.38m | 119.50m | 13.00 | -- | 8.52 | -- | -- | -1.40 | -1.40 | 0.00 | 0.7639 | 0.00 | -- | -- | 0.00 | -124.61 | -- | -170.23 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -16.64 | -- | -- | -- |
Vaxart Inc | 8.89m | -81.74m | 119.81m | 109.00 | -- | 2.15 | -- | 13.48 | -0.5431 | -0.5431 | 0.059 | 0.3155 | 0.0813 | -- | 21.67 | 81,513.76 | -74.81 | -49.60 | -86.63 | -54.86 | -- | -- | -920.00 | -1,398.00 | -- | -- | 0.0705 | -- | 6,796.26 | 12.15 | 23.47 | -- | 21.49 | -- |
Holder | Shares | % Held |
---|---|---|
Point72 Asset Management LPas of 02 May 2024 | 5.96m | 9.54% |
The Vanguard Group, Inc.as of 31 Mar 2024 | 1.48m | 2.36% |
Renaissance Technologies LLCas of 31 Mar 2024 | 637.03k | 1.02% |
BlackRock Fund Advisorsas of 31 Mar 2024 | 516.07k | 0.83% |
TowerView LLCas of 31 Mar 2024 | 382.50k | 0.61% |
Geode Capital Management LLCas of 31 Mar 2024 | 371.76k | 0.59% |
BVF Partners LPas of 31 Mar 2024 | 361.41k | 0.58% |
Morgan Stanley Smith Barney LLC (Investment Management)as of 31 Mar 2024 | 271.84k | 0.44% |
Bridgeway Capital Management LLCas of 31 Mar 2024 | 224.30k | 0.36% |
Two Sigma Advisers LPas of 31 Mar 2024 | 185.10k | 0.30% |